Phenex Pharmaceuticals AG

October ended and November began with the announcement of three new venture capital and equity funds with more than $1.3bn for health care, life science and biopharmaceutical investments. Revelation P

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OrsoBio Splurges With Four Concurrent L

Gilead Sciences Inc. unveiled Phase II data for its farnesoid X receptor (FXR) agonist GS-9674 in non-alcoholic steatohepatitis (NASH) that raise doubts for its promise in that indication compared to

When you want to develop drugs to modulate cell functions, you could do worse than to seek out and learn from the masters. This is the approach taken by French firm ENYO Pharma SAS , which has just r